Cytarabine/daunorubicin - Jazz Pharmaceuticals
Alternative Names: CPX-351; Cytarabine/daunorubicin liposomal; Cytarabine:daunorubicin - Jazz Pharmaceuticals; Cytarabine:daunorubicin liposome injection - Jazz Pharmaceuticals; Daunorubicin/cytarabine; JZP-351; Liposomal AraC-Daunorubicin CPX-351; NS 87; VYXEOS; Vyxeos; Vyxeos LiposomalLatest Information Update: 05 Nov 2023
At a glance
- Originator Celator Pharmaceuticals
- Developer Cardiff University; Celator Pharmaceuticals; Children's Oncology Group; Cincinnati Childrens Hospital Medical Center; Fred Hutchinson Cancer Research Center; Jazz Pharmaceuticals plc; National Cancer Institute (USA); Nippon Shinyaku; Pfizer; Stanford University; The Leukemia & Lymphoma Society; University of California at Irvine; University of Washington; Weill Cornell Medical College
- Class Anthracyclines; Antineoplastics; Arabinonucleosides; Cytostatic antibiotics; Daunorubicins; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Antimetabolites; DNA intercalators; DNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Acute myeloid leukaemia
- Phase III Myelodysplastic syndromes
- Phase II Precursor cell lymphoblastic leukaemia-lymphoma
- No development reported Haematological malignancies; Lymphoma
Most Recent Events
- 14 Sep 2023 Jazz Pharmaceuticals completes a phase II trial in Precursor cell lymphoblastic leukaemia lymphoma in USA (IV, Injection) (NCT03575325)
- 12 Sep 2023 Jazz Pharmaceuticals completes the V-FAST phase I trial in Acute myeloid leukaemia (First-line therapy, Combination therapy) in USA (IV) (NCT04075747)
- 21 Jun 2023 Preregistration for Acute myeloid leukaemia (First-line therapy) in Japan (IV)